inosine

Structure

Identity from ChEBI. Not evidence — none of it carries a grade.

What it touches on the way

A finding says inosine moved an endpoint. This is the biology in between: the proteins and reactions it runs through to get there. It is where to look for the two things a list of findings cannot answer — why a result might happen, and what else acts on the same machinery.

5 of these are proteins with a page of their own, and that is the door: a protein page says what else it carries, which is how one compound leads to the next.

What the reference databases state

The section above shows paths a projection assembled. This is the reference layer itself, one step from inosine: what the cleared databases state it reacts with, is carried by, is converted to and takes part in, whether or not a projection has walked it yet.

On the label

The findings above state the dose each study gave. This is the dose a label declares, which is the one a person actually meets. A label is a manufacturer’s statement about a package; nothing here says what the product does.

Each row links to its label record at the NIH Office of Dietary Supplements, which is where the declaration lives. CC0.

Every name this graph resolves to inosine. Searching any of them lands here.

Also called

9-beta-D-ribofuranosyl-9H-purin-6-ol9-beta-D-ribofuranosylhypoxanthine9-β-D-ribofuranosyl-9H-purin-6-ol9-β-D-ribofuranosylhypoxanthinehypoxanthine D-ribosidehypoxanthosine

Systematic name

(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxy-9H-purin-9-yl)tetrahydrofuran-3,4-diol9-(beta-D-ribofuranosyl)-9H-purin-6-ol9-(β-D-ribofuranosyl)-9H-purin-6-ol